All-Star Players

Wall Street

Top RNN Bull/Bear Pitches

Submitted April 20, 2010

Investors misunderstood Dr. Ahn's NYC announcement about Serdaxin results. The man used to work for the FDA and has been in scientific research all his life. He's no fool. He didn't travel all the way to NYC to try to hoodwink Wall Street. Serdaxin… More

Submitted January 15, 2014

Howdy Muggles! How's 2014 treating you so far? I've barely had time to look at the S&P this year as I'm focused on keeping my seat on the flying broomstick of biopharma. Grinding out 10% annual gains is an awesome accomplishment in the world of… More

Phase I results for Supinoxin and RX-3117 should be released later in H1 2015 and Phase 2b for Archexin in H2 2015.

The release of positive data from any of these studies will result in a significant uptick in the stock price. More importantly, a positive result from the Archexin study will generate strong partnership interest.